Status:
UNKNOWN
Study of the Inflammatory Microenvironment in Atypical Meningiomas
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Atypical Meningioma
Eligibility:
All Genders
18+ years
Brief Summary
Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy....
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- primary diagnosis of atypical meningioma
- surgery
Exclusion
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04761653
Start Date
January 1 2021
End Date
June 30 2021
Last Update
February 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guillaume GAUCHOTTE
Vandœuvre-lès-Nancy, France, 54511